Abstract:BACKGROUND & AIMS Inflammatory bowel disease (IBD) is a complex and relapsing inflammatory disease, and patients with IBD exhibit a higher risk of developing colorectal cancer (CRC). Epithelial barrier disruption is one of the major causes of IBD in which epigenetic modulation is pivotal. However, the epigenetic mechanisms underlying the epithelial barrier integrity regulation remain largely unexplored. Here, we investigated how SETD2, an epigenetic modifier, maintains intestinal epithelial homeostasis and attenuates colonic inﬂammation and tumorigenesis. METHODS GEO public database and IBD tissues were used to investigate the clinical relevance of SETD2 in IBD. To define a role of SETD2 in the colitis, we generated mice with epithelium-specific deletion of Setd2 ( Setd2 Vil-KO mice). Acute colitis was induced by 2% dextran sodium sulfate (DSS), and colitis-associated CRC was induced by injecting azoxymethane (AOM), followed by three cycles of 2% DSS treatments. Colon tissues were collected from mice and analyzed by histology, immunohistochemistry and immunoblots. Organoids were generated from Setd2Vil-KO and control mice, and were stained with 7-AAD to detect apoptosis. A fluorescent probe, 2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCFDA), was used to detect the levels of ROS in intestinal epithelial cells (IECs) isolated from the two types of mice. RNA-seq and H3K36me3 ChIP-seq analyses were performed to identify the mis-regulated genes modulated by SETD2. Results were validated in functional rescue experiments by N-acetyl-l-cysteine (NAC) treatment and transgenes expression in IECs. RESULTS SETD2 expression became decreased in IBD patients and DSS-treated colitis mice. Setd2 Vil-KO mice displayed abnormal loss of mucus-producing goblet cells and antimicrobial peptide (AMP)-producing Paneth cells, and exhibited pre-mature intestinal inflammation development. Consistent with the reduced SETD2 expression in IBD patients, Setd2 Vil-KO mice showed increased susceptibility to DSS-induced colitis, accompanied by more severe epithelial barrier disruption and markedly increased intestinal permeability that subsequently facilitated inﬂammation-associated CRC. Mechanistically, deletion of Setd2 resulted in excess reactive oxygen species (ROS), which led to cellular apoptosis and defects in barrier integrity. NAC treatment in Setd2 Vil-KO mice rescued epithelial barrier injury and apoptosis. Importantly, Setd2 depletion led to excess ROS by directly down-regulating antioxidant genes that inhibit ROS reaction. Moreover, overexpression of antioxidant PRDX6 in Setd2 Vil-KO IECs largely alleviated the overproductions of ROS and improved the cellular survival. CONCLUSIONS Deficiency of Setd2 specifically in the intestine aggravates epithelial barrier disruption and inflammatory response in colitis via a mechanism dependent on oxidative stress. Thus, our results highlight an epigenetic mechanism by which Setd2 modulates oxidative stress to regulate intestinal epithelial homeostasis. SETD2 might therefore be a pivotal regulator that maintains the homeostasis of the intestinal mucosal barrier. ### Competing Interest Statement The authors have declared no competing interest. * AMP : antimicrobial peptide AOM : azoxymethane 7-AAD : 7- aminoactinomycin D CD : Crohn’s disease CRC : colorectal cancer DSS : dextran sodium sulfate GO : gene ontology H2DCFDA : 2′,7′-dichlorodihydroﬂuorescein diacetate H3K36 : histone H3 lysine 36 IBD : inflammatory bowel disease IEC : intestinal epithelial cell NAC : N-acetyl-l-cysteine 8-OHdG : 8-oxo-2’- deoxyguanosine PRDX : peroxiredoxin ROS : reactive oxygen species RT-qPCR : Real-Time quantitative PCR UC : ulcerative colitis ZO-1 : tight junction protein 1.

SETD8 involved in the progression of IBD via epigenetically regulating p62 expression

PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization

Methyltransferase Setd2 Prevents T Cell-Mediated Autoimmune Diseases Via Phospholipid Remodeling

The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis

The Histone Methyltransferase SETD2 Modulates Oxidative Stress to Attenuate Colonic Inflammation and Tumorigenesis in Mice

Dysregulated Lysine Acetyltransferase 2b Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10

Epithelial Ezh2 Serves As An Epigenetic Determinant In Experimental Colitis By Inhibiting Tnf Alpha-Mediated Inflammation And Apoptosis

Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10.

Isosteviol Attenuates DSS-induced Colitis by Maintaining Intestinal Barrier Function Through PDK1/AKT/NF-κB Signaling Pathway

P037 USP16-mediated deubiquitination of calcineurin A controls peripheral T cells maintenance and attenuates intestinal inflammation

Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease

Mo1749 Epigenetic Regulation in Inflammatory Bowel Disease Pathogenesis - A Novel Connection by Lysine Acetyltransferase 2B

Epithelial CRL4 DCAF2 is Critical for Maintaining Intestinal Homeostasis Against DSS-Induced Colitis by Regulating the Proliferation and Repair of Intestinal Epithelial Cells

New Insights Into the Epigenetic Regulation of Inflammatory Bowel Disease

Protein arginine methyltransferase 2 (PRMT2) promotes dextran sulfate sodium‐induced colitis by inhibiting the SOCS3 promoter via histone H3R8 asymmetric dimethylation

Btbd8 deficiency reduces susceptibility to colitis by enhancing intestinal barrier function and suppressing inflammation

The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe?

MPST deficiency promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via AKT

Deubiquitinase USP14 is upregulated in Crohn's disease and inhibits the NOD2 pathway mediated inflammatory response in vitro

miRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism.

Downregulation of OCTN2 by cytokines plays an important role in the progression of inflammatory bowel disease.